Concurrent Cetuximab and Bevacizumab Therapy in a Murine Orthotopic Model of Anaplastic Thyroid Carcinoma
- 1 April 2007
- journal article
- research article
- Published by Wiley in The Laryngoscope
- Vol. 117 (4) , 674-679
Abstract
Objective: To evaluate the therapeutic efficacy of bevacizumab and cetuximab, alone and in combination, in an orthotopic model of anaplastic thyroid carcinoma (ATC) in athymic nude mice.Study Design and Setting: This was a randomized, controlled in vivo study.Materials and Methods: The ATC cell line, ARO, was used to establish orthotopic xenografts of ATC in athymic nude mice. Mice were randomized to therapy for 4 weeks in one of four treatment groups: placebo, cetuximab, bevacizumab, or the combination of cetuximab and bevacizumab. A second study compared the antitumor efficacy of the cetuximab‐bevacizumab combination with doxorubicin. In both studies, tumor volumes on completion were measured and compared. Immunohistochemical analysis was performed with antiCD31 and antiproliferating cell nuclear antigen (PCNA) antibodies to assess the in vivo mechanisms of action of these agents.Results: Cetuximab decreased the production of vascular endothelial growth factor by ATC cell lines in vitro. Mean tumor volumes for the control, bevacizumab, cetuximab, and combination groups at the end of the in vivo study were 291, 213, 94, and 42 mm3, respectively. The differences in mean tumor volume for the control versus treatment groups were statistically significant. Immunohistochemical analysis showed decreased microvessel density and PCNA positivity in the treatment groups. In the doxorubicin comparison study, mean tumor volumes for control, doxorubicin, and combination antibody treatment groups were 175, 162, and 22 mm3, respectively.Conclusions: Cetuximab and bevacizumab alone and in combination inhibit tumor growth and angiogenesis in an in vivo model of ATC. Also, this therapy was superior to doxorubicin therapy.Keywords
This publication has 11 references indexed in Scilit:
- Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788Molecular Cancer Therapeutics, 2005
- An Orthotopic Model of Anaplastic Thyroid Carcinoma in Athymic Nude MiceClinical Cancer Research, 2005
- Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid CancerClinical Cancer Research, 2004
- Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib (‘Iressa’, ZD1839)Cancer Science, 2004
- Review of epidermal growth factor receptor biologyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- Modulation of Tumor Growth and Tumor Induced Angiogenesis After Epidermal Growth Factor Receptor Inhibition by ZD1839 in Renal Cell CarcinomaJournal of Urology, 2004
- Anaplastic thyroid cancerCurrent Opinion in Oncology, 2003
- Vascular Endothelial Growth Factor Monoclonal Antibody Inhibits Growth of Anaplastic Thyroid Cancer Xenografts in Nude MiceThyroid®, 2002
- Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse modelEuropean Journal of Cancer, 2002
- Epidermal Growth Factor Receptor Signaling Activates Met in Human Anaplastic Thyroid Carcinoma CellsExperimental Cell Research, 2000